Sunpharma launches Favipiravir pill Fluguard to deal with gentle to average COVID-19 infections at Rs 35 per tablet
Favipiravir is an antiviral drug that was initially made to deal with influenza in Japan beneath the model identify Avigan.
Solar Pharmaceutical Industries has introduced that it’ll now be promoting Favipiravir beneath the identify FluGuard for the remedy of gentle to average circumstances of the coronavirus an infection. The 200 mg tablets are priced at Rs 35 per dose.
Favipiravir is an antiviral drug that was initially made to deal with influenza in and developed by Japan’s Fujifilm Holdings Corp beneath the model identify Avigan. Additionally it is marketed in Russia and China. On 19 June, it was accepted for emergency medical use in treating sufferers with gentle to average Covid-19 illness by the Drug Controller Basic of India (DCGI).
“With over 50,000 Covid-19 circumstances being reported each day in India, there may be an pressing want to offer extra remedy choices to healthcare professionals,” Kirti Ganorkar, CEO of Solar Pharma’s India enterprise stated in a press assertion. “We’re launching FluGuard® at a cheap value to make the drug accessible to increasingly more sufferers thereby decreasing their monetary burden,” she added.
The pill shall be obtainable out there from this week.
Glenmark’s FabiFlu, one other Favipiravir-based remedy, has dropped its costs and is now obtainable at ₹75 a pill, in comparison with the ₹103 per pill it costed when it was launched into the market in June 2020.
Favipiravir has reportedly confirmed anti-viral exercise towards all subtypes of influenza virus strains.
Not solely does it inhibit replication of influenza A and B, the drug has additionally proven promise within the remedy of avian influenza, and as an alternative choice to deal with influenza strains proof against the primary selection of remedy. For influenza remedy, sufferers are given a 1600 mg dose of this drug on Day 1 and about 600 mg dose from day 2 to day 5.
The flexibleness that favipiravir exhibits in its skill to behave on a number of completely different influenza viruses has led to different international locations utilizing the drug to discover therapies for novel (rising) viruses together with Ebola and most just lately, COVID-19.
Nonetheless, outdoors its effectiveness in treating the influenza virus, proof in help of this drug continues to be scant and preliminary.
#Sunpharma #launches #Favipiravir #pill #Fluguard #deal with #gentle #average #COVID19 #infections #tablet